Zevra Therapeutics (ZVRA) Other financing activities (2015 - 2026)

Zevra Therapeutics (ZVRA) has 9 years of Other financing activities data on file, last reported at $9.2 million in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (changed N/A YoY) and the FY2025 annual result came in at $8.6 million, changed N/A from the prior year.
• Other financing activities climbed to $9.2 million in Q1 2026, from $5.1 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $9.2 million in Q1 2026 to a low of -$1.3 million in Q4 2024.
• A 5-year average of $1.7 million and a median of $216000.0 in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities plunged 130200.0% — and 2025, when it surged 492.86%.
• Tracing ZVRA's Other financing activities over 5 years: stood at $108000.0 in 2022, then tumbled by 100.93% to -$1000.0 in 2023, then sank by 130200.0% to -$1.3 million in 2024, then surged by 492.86% to $5.1 million in 2025, then surged by 79.16% to $9.2 million in 2026.
• The last three Other financing activities figures came in at $9.2 million (Q1 2026), $5.1 million (Q4 2025), and $573000.0 (Q3 2025), per Business Quant data.